



PRELIMINARY SCIENTIFIC PROGRAM (Subject to changes – as of December 7, 2023)

THURSDAY, MARCH 21, 2024		
08:20-11:00	Neuroimmunology 1	HALL A
Chairs:	Bruno Gran , UK; Olaf Stuve , USA	
08:20-09:10	Is Hashimoto's encephalitis/encephalopathy a valid construct in 2024?	
08:20-08:30	Moderator: Uros Rot , Slovenia Introduction and Pre-Debate Voting	
08:30-08:45	Yes: Alasdair Coles , UK	
08:45-09:00	No: Divyanshu Dubey , USA	
09:00-09:10	Discussion, Rebuttals and Post-Debate Voting	
09:10-10:00	All patients with inflammatory optic neuritis should be screened for AQP4-IgG and MOG-IgG antibodies	
09:10-09:20	Moderator: Ruth Gerales , UK Introduction and Pre-Debate Voting	
09:20-09:35	Yes: Uros Rot , Slovenia	
09:35-09:50	No: Saif Huda , UK	
09:50-10:00	Discussion, Rebuttals and Post-Debate Voting	
10:00-10:50	A prolonged (1 year) corticosteroid taper is sufficient to prevent relapses in patients with MOGAD	
10:00-10:10	Moderator: Joab Chapman , Israel Introduction and Pre-Debate Voting	
10:10-10:25	Yes: Michael Levy , USA	
10:25-10:40	No: Friedemann Paul , Germany	
10:40-11:00	Discussion, Rebuttals and Post-Debate Voting	
11:00-11:30	Coffee Break, Exhibition & e-Posters Visit	

11:30-12:00	Opening ceremony	HALL A
11:35-11:40	<u>Natan Bornstein</u> , Israel	
11:40-11:45	<u>Anthony Schapira</u> , UK	
11:45-11:50	<u>Amos Korczyn</u> , Israel	
11:50-11:55	<u>Richard J Davenport</u> , UK	
11:55-13:00	Plenary Session	HALL A
ChairS	<u>Brian G. Weinshenker</u> , USA; <u>John Hardy</u> , UK <i>CONy Excellence Recognition Award to Prof. Angela Vincent.</i>	
12:00-12:30	Antibody-mediated diseases: past, present and questions for the future <u>Angela Vincent</u> , UK	
12:30-13:00	The neurological manifestations of Covid-19 <u>Mike Zandi</u> , UK	
13:00-14:00	Industry Sponsored Symposium	HALL A
14:00-14:50	MTE	
14:00-14:50	Lunch Break, Exhibition & e-Posters Visit	
14:50-16:30	Antibody testing	HALL A
Chairs:	<u>Brian G. Weinshenker</u> , USA; <u>Mike Zandi</u> , UK	
14:50-15:40	Is long COVID an autoimmune disease?	
14:50-15:00	Moderator: <u>Tom Pollak</u> , UK Introduction and Pre-Debate Voting	
15:00-15:15	Yes: <u>Michael D. Geschwind</u> , USA	
15:15-15:30	No : <u>Hans-Peter Hartung</u> , Germany	
15:30-15:40	Discussion, Rebuttals and Post-Debate Voting	
15:40-16:30	Is it required to send focused antibody testing on patients with suspected autoimmune encephalitis, or should all patients be screened with a panel of antibody tests?	
15:40-15:50	Moderator: <u>Abhijit Chaudhuri</u> , UK Introduction and Pre-Debate Voting	
15:50-16:05	Yes: <u>Eoin Flanagan</u> , USA	
16:05-16:20	No: <u>Ruth Gerales</u> , UK	
16:20-16:30	Discussion, Rebuttals and Post-Debate Voting	
16:30-16:50	Coffee Break, Exhibition & e-Posters Visit	

16:50-18:30	Corticosteroid treatment	HALL A
Chair:	Friedemann Paul , Germany	
16:50-17:40	Diabetes mellitus-associated plexopathy is an inflammatory vasculitis and should be treated with high dose corticosteroids	
16:50-17:00	Moderator: Divyanshu Dubey , USA Introduction and Pre-Debate Voting	
17:00-17:15	Yes: Jim Dyck , USA	
17:15-17:30	No: Alasdair Coles ,UK	
17:30-17:40	Discussion, Rebuttals and Post-Debate Voting	
17:40-18:30	Cerebral amyloid angiopathy (CAA) may lead to inflammatory vasculopathy; patients with cerebral amyloid angiitis should receive corticosteroids on diagnosis.	
17:10-17:50	Moderator: Friedemann Paul , Germany	
17:50-18:05	Yes: Joab Chapman , Israel	
18:05-18:20	No: Abhijit Chaudhuri , UK	
18:20-18:30	Discussion, Rebuttals and Post-Debate Voting	
18:30	Networking Reception (Exhibition Area)	

THURSDAY, MARCH 21, 2024		
08:20 – 11:00	Parkinson's disease (PD)	HALL B
Chairs:	Cristian Falup-Pecurariu , Romania; Hana Brozova , Czech Republic	
08:20-09:10	Has the DLB vs. PD(D) distinction outlived its usefulness?	
08:20-08:30	Moderator: Viktoriia Gryb , Ukraine Introduction and Pre-Debate Voting	
08:30-08:45	Yes: Lea Grinberg , USA	
08:45-09:00	No: Vladimira Vuletic , Croatia	
09:00-09:10	Discussion, Rebuttals and Post-Debate Voting	
09:10-10:00	With the limitation of dopamine-based therapy, should therapy in PD be directed in other directions?	
09:10-09:20	Moderator: Michael Ugrumov , Russia Introduction and Pre-Debate Voting	
09:20-09:35	Yes: Jaroslav Slawek , Poland	
09:35-09:50	No: Heinz Reichmann , Germany	
09:50-10:00	Discussion, Rebuttals and Post-Debate Voting	
10:00-10:50	Is it possible to modify the disease course in PD?	
10:00-10:10	Moderator: Avner Thaler , Israel Introduction and Pre-Debate Voting	
10:10-10:25	Yes: Daniel Weintraub , USA	
10:25-10:40	No: Jaroslav Slawek , Poland	
10:40-10:50	Discussion, Rebuttals and Post-Debate Voting	
11:00-11:30	Coffee Break, Exhibition & e-Posters Visit	
11:30-12:00	Opening ceremony (Hall A)	
12:00-13:00	Plenary Session (Hall A)	
13:00-14:00	Industry Sponsored Symposium (Hall A)	
14:00-14:50	MTE	
14:00-14:50	Lunch Break, Exhibition & e-Posters Visit	

14:50-16:30	Precision therapies in PD	HALL B
Chair:	<u>Gilad Yahalom</u> , Israel	
14:50-15:40	Are we ready for precision medicine in PD?	
14:50-15:00	Moderator: <u>Yoav Ben-Shlomo</u> , UK Introduction and Pre-Debate Voting	
15:00-15:15	Yes: <u>Ray Chaudhuri</u> , UK	
15:15-15:30	No: <u>Evzen Ruzicka</u> , Czech Republic	
15:30-15:40	Discussion, Rebuttals and Post-Debate Voting	
15:40-16:30	GBA targeted therapies are a waste of money	
15:40-15:50	Moderator: <u>Ziv Gan-Or</u> , Canada Introduction and Pre-Debate Voting	
15:50-16:05	Yes: <u>Avner Thaler</u> , Israel	
16:05-16:20	No : <u>Anthony Schapira</u> , UK	
16:20-16:30	Discussion, Rebuttals and Post-Debate Voting	
16:30-16:50	Coffee Break, Exhibition & e-Posters Visit	
16:50-18:30	PD 3	HALL B
Chairs:	<u>Yehonatan Sharabi</u> , Israel; <u>Denis Pokhabov</u> , Russia	
16:50-17:40	Telemedicine is valuable for PD patients care and will become the predominant method	
16:50-17:00	Moderator: <u>Yoav Ben-Shlomo</u> , UK Introduction and Pre-Debate Voting	
17:00-17:15	Yes: <u>Heinz Reichmann</u> , Germany	
17:15-17:30	No: <u>Anthony Schapira</u> , UK	
17:30-17:40	Discussion, Rebuttals and Post-Debate Voting	
17:40-18:30	Should idiopathic REM-sleep behavior disorder (iRBD) patients be informed about potential PD prognosis as long as there is no disease modifying therapy (DMT) ?	
17:10-17:50	Moderator: <u>Ray Chaudhuri</u> , UK	
17:50-18:05	Yes: <u>Ivana Rosenzweig</u> , UK	
18:05-18:20	No: <u>Danielle Wasserman Berk</u> , Israel	
18:20-18:30	Discussion, Rebuttals and Post-Debate Voting	

THURSDAY, MARCH 21, 2024		
08:20 – 11:00	Alzheimer's disease (AD): Biomarkers	HALL C
Chairs:	<u>Ivan Milanov</u> , Bulgaria <u>Marina Janelidze</u> , Georgia	
08:20-09:10	Biomarkers are useful in subjective cognitive complaints and should be tested in each patient	
08:20-08:30	Moderator: <u>Tom Neylan</u> , USA Introduction and Pre-Debate Voting	
08:30-08:45	Yes: <u>Paul Edison</u> , UK	
08:45-09:00	No: <u>Zvezdan Pirtosek</u> , Slovenia	
09:00-09:10	Discussion, Rebuttals and Post-Debate Voting	
09:10-10:00	Are serum markers such as phospho-tau useful in diagnosing AD ?	
09:10-09:20	Moderator: <u>Xiaoping Wang</u> , People's Republic of China Introduction and Pre-Debate Voting	
09:20-09:35	Yes: <u>Robert Perneczky</u> , Germany	
09:35-09:50	No: <u>Arfan Ikram</u> , The Netherlands	
09:50-10:00	Discussion, Rebuttals and Post-Debate Voting	
10:00-11:00	AA session Moderators: <u>Claire Sexton</u> , USA; <u>Lea Grinberg</u> , USA	
	Sleep as risk factor - evidence and interventions: <u>Sharon Naismith</u> , Australia	
	Neuropathology and neuroimaging of sleep: <u>Neus Falgas</u> , Spain	
	Sleep in clinical populations: <u>Tom Neylan</u> , USA	
11:00-11:30	Coffee Break, Exhibition & e-Posters Visit	
11:30-12:00	Opening ceremony	
12:00-13:00	Plenary Session (Hall A)	
13:00-14:00	Industry Sponsored Symposium (Hall A)	
13:00-14:00	MTE	
14:00-14:50	Lunch Break, Exhibition & e-Posters Visit	

14:50-16:30	AD: Therapy	HALL C
Chairs:	<u>Panteleimon Giannakopoulos</u> , Switzerland ; <u>Nazia Mumtaz</u> , Pakistan	
14:50-15:40	Obstructive sleep apnea is detrimental in patients with dementia and should always be treated	
14:50-15:00	Moderator: <u>Michael D. Geschwind</u> , USA Introduction and Pre-Debate Voting	
15:00-15:15	Yes: <u>Ivana Rosenzweig</u> , UK	
15:15-15:30	No: <u>Sharon Naismith</u> , Australia	
15:30-15:40	Discussion, Rebuttals and Post-Debate Voting	
15:40-16:30	Is cognitive reserve a useful term?	
15:40-15:50	Moderator: <u>Robert Perneczky</u> , Germany Introduction and Pre-Debate Voting	
15:50-16:05	Yes: <u>Yaakov Stern</u> , USA	
16:05-16:20	No: <u>Amos Korczyn</u> , Israel	
16:20-16:30	Discussion, Rebuttals and Post-Debate Voting	
16:30-16:50	Coffee Break, Exhibition & e-Posters Visit	
16:50-18:30	AD 3	HALL C
Chairs:	<u>Judith Aharon</u> , Israel; <u>Milica G. Kramberger</u> , Slovenia	
16:50-17:40	Antiamyloid drugs have only a very limited effect and will not be clinically useful for most patients	
16:50-17:00	Moderator: <u>John Hardy</u> , UK Introduction and Pre-Debate Voting	
17:00-17:15	Yes: <u>Dorota Religa</u> , Sweden	
17:15-17:30	No: <u>Paul Edison</u> , UK	
17:30-17:40	Discussion, Rebuttals and Post-Debate Voting	
17:40-18:30	Prevention of dementia: Multidomain intervention or personalized approach ?	
17:10-17:50	Moderator: <u>Miia Kivipelto</u> , Sweden Introduction and Pre-Debate Voting	
17:50-18:05	Multidomain intervention: <u>Alina Solomon</u> , Finland	
18:05-18:20	Personal approach: <u>Dag Aarsland</u> , UK	
18:20-18:30	Discussion, Rebuttals and Post-Debate Voting	

FRIDAY, MARCH 22,2024		
08:30-11:00	STROKE	HALL A
Chair:	Vida Demarin, Croatia	
08:30-09:20	In people with intracerebral hemorrhage (ICH) minimally invasive neurosurgery should be routinely discussed	
08:30-08:40	Moderator: Robert Mikulik, Czech republic Introduction and Pre-Debate Voting	
08:40-08:55	Yes: Marina Roje Bedekovic, Croatia	
08:55-09:10	No: Laszlo Csiba, Hungary	
09:10-09:20	Discussion, Rebuttals and Post-Debate Voting	
09:20-10:10	Should we aggressively treat asymptomatic small vessels disease (SVD)?	
09:20-09:30	Moderator: Ashfaq Shuaib, Canada Introduction and Pre-Debate Voting	
09:30-09:45	Yes: Christine Kremer, Sweden	
09:45-10:00	No: Alan Cameron,UK	
10:00-10:10	Discussion, Rebuttals and Post-Debate Voting	
10:10-11:00	Is there an added value to use virtual reality in rehabilitation after stroke?	
10:00-10:20	Moderator: Nirmal Surya, India Introduction and Pre-Debate Voting	
10:20-10:35	Yes: Volker Homberg, Germany	
10:35-10:50	No: Dafin Muresanu, Romania	
10:50-11:00	Discussion, Rebuttals and Post-Debate Voting	
11:00-11:30	Coffee Break, Exhibition & e-Posters Visit	
11:30-12:00	Plenary Session	HALL A
Chair:	Lea Grinberg USA, Brazil ;	
11:30-12:00	Sleep disorders and brain health Claudio Bassetti, Switzerland	
12:00-12:30	The use of AI in neurology . Sanjay Budheo, UK	
12:30-13:30	Industry Sponsored Symposium	HALL A
13:30-14:30	MTE	
13:30-14:30	Lunch Break, Exhibition & e-Posters Visit	

14:30-16:10	Stroke	HALL A
Chairs:	Christine Kremer , Sweden; Marina Roje Bedekovic , Croatia	
14:30-15:20	Mechanical Thrombectomy (MT) for large core infarcts is a worthwhile use of health care resources	
14:30-14:40	Moderator: Laszlo Csiba , Hungary Introduction and Pre-Debate Voting	
14:40-14:55	Yes: Ashfaq Shuaib , Canada	
14:55-15:10	No: Phil White , UK	
15:10-15:20	Discussion, Rebuttals and Post-Debate Voting	
15:20-16:10	Can GLP-1 agonists be used to reduce stroke risk in non-diabetic obese individuals?	
15:20-15:30	Moderator: Vida Demarin , Croatia Introduction and Pre-Debate Voting	
15:30-15:45	Yes: Natan Bornstein , Israel	
15:45-16:00	No: Jesse Dawson , UK	
16:00-16:10	Discussion, Rebuttals and Post-Debate Voting	
16:10-16:30	Coffee Break, Exhibition & e-Posters Visit	
16:10-18:10	STROKE 3	HALL A
Chairs:	Laszlo Csiba , Hungary	
16:30-17:20	Should patients with mild non-disabling stroke admitted within 4.5h be considered for thrombolysis?	
16:30-16:40	Moderator: Robert Mikulik , Czech Republic	
16:40-16:55	Yes: Derk Krieger , UAE	
16:55-17:10	NO: Jesse Dawson , UK	
17:10-17:20	Discussion, Rebuttals and Post-Debate Voting	

FRIDAY, MARCH 22, 2024		
08:30-11:00	HEADACHE : Migraine and cluster headache	HALL B
Chair:	<u>Vlasta Vukovic Cvetkovic</u> , Denmark	
08:30-09:20	Are anti-CGRP mAbs effective in prevention of cluster headache?	
08:30-08:40	Moderator: <u>Dimos Mitsikostas</u> , Greece Introduction and Pre-Debate Voting	
08:40-08:55	YES: <u>Giorgio Lambru</u> , UK	
08:55-09:10	NO: <u>Patricia Pozo-Rosich</u> , Spain	
09:10-09:20	Discussion, Rebuttals and Post-Debate Voting	
09:20-10:10	Premonitory symptoms in migraine and cluster headache are important for treatment	
09:20-09:30	Moderator: <u>Cristina Tassorelli</u> , Italy Introduction and Pre-Debate Voting	
09:30-09:45	YES: <u>Anna Andreou</u> , UK	
09:45-10:00	NO: <u>Haakan Ashina</u> , Denmark	
10:00-10:10	Discussion, Rebuttals and Post-Debate Voting	
10:10-11:00	Is central 5-HT _{1F} agonism essential for ditans to be effective?	
10:00-10:20	Moderator: <u>Dimos Mitsikostas</u> , Greece Introduction and Pre-Debate Voting	
10:20-10:35	Yes: <u>Anna Andreou</u> , UK	
10:35-10:50	No: <u>Antoinette Maassen van den Brink</u> , The Netherlands	
10:50-11:00	Discussion, Rebuttals and Post-Debate Voting	
11:00-11:30	Coffee Break, Exhibition & e-Posters Visit	
11:30-12:30	Plenary Sessions (Hall A)	
12:30-13:30	Industry Sponsored Symposium (Hall A)	
13:30-14:30	MTE	
13:30-14:30	Lunch Break, Exhibition & e-Posters Visit	

14:30-16:10	HEADACHE : Ditans and Gepants	HALL B
Chairs:	Marjan Zaletel , Slovenia ; Tomas Nezadal , Czech Republic	
14:30-15:20	Addition of a gepant for the acute care of migraine attacks is safe and effective in patients on anti-CGRP mAbs	
14:30-14:40	Moderator: Messoud Ashina , Denmark Introduction and Pre-Debate Voting	
14:40-14:55	Yes: Cristina Tassorelli , Italy	
14:55-15:10	No: Gisela Terwindt , Holland	
15:10-15:20	Discussion, Rebuttals and Post-Debate Voting	
15:20-16:10	Are gepants and ditans efficacious and safe for people with vascular risk factors?	
15:20-15:30	Moderator: Messoud Ashina , Denmark Introduction and Pre-Debate Voting	
15:30-15:45	Yes: Jose Miguel Lainez , Italy	
15:45-16:00	No: Gisela Terwindt , The Netherlands	
16:00-16:10	Discussion, Rebuttals and Post-Debate Voting	
16:10-16:30	Coffee Break, Exhibition & e-Posters Visit	
16:30-18:10	Medication overuse headache and artificial intelligence	HALL B
Chair:	Licia Grazi , Italy	
16:30-17:20	Is Artificial Intelligence (AI) ready for inclusion in headache management?	
16:30-16:40	Moderator: Alan Rapoport , USA Introduction and Pre-Debate Voting	
16:40-16:55	Yes: Rob Cowan , USA	
16:55-17:10	No: Morris Levin , USA	
17:10-17:20	Discussion, Rebuttals and Post-Debate Voting	
17:20-18:10	Is it necessary to detoxify most patients with Medication Overuse Headache (MOH) in order to achieve success?	
17:20-17:30	Moderator: Cristina Tassorelli , Italy Introduction and Pre-Debate Voting	
17:30-17:45	Yes: Morris Levin , USA	
17:45-18:00	No: Alan Rapoport , USA	
18:00-18:10	Discussion, Rebuttals and Post-Debate Voting	

SATURDAY,MARCH 23,2024		
08:20-11:00	Amyotrophic lateral sclerosis (ALS)	HALL A
Chair:	Pam Shaw, UK	
08:20-09:10	Is primary lateral sclerosis part of the ALS continuum or a different disease?	
08:20-08:30	Moderator: Albert Ludolph, Germany Introduction and Pre-Debate Voting	
08:30-08:45	Yes: Orla Hardiman,Ireland	
08:45-09:00	No: Amir Dori, Israel	
09:00-09:10	Discussion, Rebuttals and Post-Debate Voting	
09:10-10:00	Human cell models are better than mouse models in therapy development for ALS/MND	
09:10-09:20	Moderator: Amos Korczyn, Israel Introduction and Pre-Debate Voting	
09:20-09:35	Yes : Pam Shaw, UK	
09:35-09:50	No: Linda Greensmith,UK	
09:50-10:00	Discussion, Rebuttals and Post-Debate Voting	
10:00-11:00	ALS treatments have to demonstrate efficacy on both prolonging survival and slowing disease progression	
10:00-10:10	Moderator: Amir Dori , Israel Introduction and Pre-Debate Voting	
10:10-10:25	Yes: Albert Ludolph, Germany	
10:25-10:40	No: Osman Sinanovic, Bosnia and Herzegovina	
10:40-11:00	Discussion, Rebuttals and Post-Debate Voting	
11:00-11:30	Coffee Break, Exhibition & e-Posters Visit	
11:30-12:30	Plenary Session	HALL A
11:30-12:00	Aphantasia – when all is dark in the mind’s eye Adam Zeman, UK	
12:00-12:30	The impossible pricing of anti-amyloid medication. A global challenge. Paola Barbarino, UK	
12:30-13:30	Industry Sponsored Symposium	HALL A
13:30-14:30	MTE	
13:30-14:30	Lunch Break, Exhibition & e-Posters Visit	

14:30- 16:10	Amyotrophic lateral sclerosis (ALS) 2	HALL A
Chair:	Ervin Jancic , Croatia	
14:30-15:20	The euphoria on personalized ALS treatment with Antisense oligonucleotides (ASO) is premature	
14:30-14:40	Moderator: Osman Sinanovic , Bosnia and Herzegovina Introduction and Pre-Debate Voting	
14:40-14:55	Yes: Pam Shaw , UK	
14:55-15:10	No: Giancarlo Logroscino , Italy	
15:10-15:20	Discussion, Rebuttals and Post-Debate Voting	
15:20-16:10	Tracheostomy ventilation in ALS/MND should be offered to all patients	
15:20-15:30	Moderator: Pam Shaw , UK Introduction and Pre-Debate Voting	
15:30-15:45	YES: Giancarlo Logroscino , Italy	
15:45-16:00	No: Amos Korczyn , Israel	
16:00-16:10	Discussion, Rebuttals and Post-Debate Voting	
16:10-16:30	Coffee Break, Exhibition & e-Posters Visit	
16:10-18:10	Neurodegenerative diseases	HALL A
Chairs:	Bogdan Popescu , Romania	
16:30-17:20	Will anti-tau drugs be useful in fighting tau-driven diseases?	
16:30-16:40	Moderator: Bogdan Popescu , Romania Introduction and Pre-Debate Voting	
16:40-16:55	Yes: Lea Grinberg , USA	
16:55-17:10	No : Jesse Cedarbaum , USA	
17:10-17:20	Discussion, Rebuttals and Post-Debate Voting	
17:20-18:10	Pathological changes in microglia were linked to pathology in different neurodegenerative diseases. Can we target microglia to develop a therapeutic approach?	
17:20-17:30	Moderator: Davis Atwell , UK Introduction and Pre-Debate Voting	
17:30-17:45	Yes: Dan Frenkel , Israel	
17:45-18:00	No: Bogdan Popescu , Romania	
18:00-18:10	Discussion, Rebuttals and Post-Debate Voting	

SATURDAY, MARCH 23, 2024		
08:20-11:00	Epilepsy: Drug treatment	HALL B
Chairs:	Matthias Koepp , UK	
08:20-09:10	Should we routinely utilize therapeutic drug monitoring when prescribing drug therapy for people with epilepsy?	
08:20-08:30	Moderator: Michael Sperling , USA Introduction and Pre-Debate Voting	
08:30-08:45	Yes: William Theodore , USA	
08:45-09:00	No: Elinor Ben-Menachem , Sweden	
09:00-09:10	Discussion, Rebuttals and Post-Debate Voting	
09:10-10:00	Should women who wish to become pregnant be prescribed supplemental folic acid? Rationale: A recent study suggests that cancer risk is increased in children born to women who took folic acid during pregnancy. Is this study sufficient to alter clinical practice?	
09:10-09:20	Moderator: Alla Guekht , Russia Introduction and Pre-Debate Voting	
09:20-09:35	Yes: Jacqueline French , USA	
09:35-09:50	No: Beate Diehl , UK	
09:50-10:00	Discussion, Rebuttals and Post-Debate Voting	
10:00-11:00	Should polytherapy be used early, after one drug has failed to control seizures?	
10:00-10:10	Moderator: Zeljka Petelin-Gadze , Croatia Introduction and Pre-Debate Voting	
10:10-10:25	Yes: Manjari Tripathi , India	
10:25-10:40	No: Elinor Ben-Menachem , Sweden	
10:40-10:50	Discussion, Rebuttals and Post-Debate Voting	
11:00-11:30	Coffee Break, Exhibition & e-Posters Visit	
11:30-12:30	Plenary Sessions (Hall A)	
12:30-13:30	Industry Sponsored Symposium (Hall A)	
13:30-14:30	MTE	
13:30-14:30	Lunch Break, Exhibition & e-Posters Visit	

14:30-16:10	The unusual cases	HALL B
Chair:	<u>Nandan Yardi</u> , India	
14:30-15:20	Mix of interesting cases related to diagnosis and management challenges in epilepsy, discussing advanced drug therapy and a modes of administration. Case Studies: Michael Sperling	
15:20-16:10	Should we prefer one method of neurostimulation over others?	
15:20-15:30	Moderator: <u>Alla Guekht</u> , Russia Introduction and Pre-Debate Voting	
15:30-15:45	Yes: <u>Martin Holtkamp</u> , Germany	
15:45-16:00	No: <u>Ivan Rektor</u> , Czech republic	
16:00-16:10	Discussion, Rebuttals and Post-Debate Voting	
16:10-16:30	Coffee Break, Exhibition & e-Posters Visit	
16:30-18:10	Epilepsy 3	HALL B
Chairs:	<u>Man Mohan Mehndiratta</u> , India; <u>Andreja Bujan Kovac</u> , Croatia	
16:30-17:20	Should laser interstitial thermal ablation therapy (LITT) be preferred over open surgery, either anterior temporal lobectomy or amygdalohippocampectomy, for mesial temporal sclerosis?	
16:30-16:40	Moderator: <u>Lilac Goldstein</u> , Israel Introduction and Pre-Debate Voting	
16:40-16:55	Yes: <u>Michael Sperling</u> , USA	
16:55-17:10	No: <u>Matthias Koepp</u> , UK	
17:10-17:20	Discussion, Rebuttals and Post-Debate Voting	
17:20-18:10	Should intracranial EEG be largely restricted to patients with non-lesional epilepsy unless there is discordance between the lesion and the scalp EEG?	
17:20-17:30	Moderator: <u>Matthias Koepp</u> , UK Introduction and Pre-Debate Voting	
17:30-17:45	Yes: <u>William Theodore</u> , USA	
17:45-18:00	No: <u>Ivan Rektor</u> , Czech republic	
18:00-18:10	Discussion, Rebuttals and Post-Debate Voting	

SATURDAY, MARCH 23, 2024		
08:20-11:00	Multiple sclerosis: drug therapy	HALL C
Chair:	Jacek Losy , Poland	
08:20-09:10	Radiologically isolated syndrome (RIS): Disease modifying therapies (DMT) should only be started when symptoms have occurred	
08:20-08:30	Moderator: Alicia Kalinowska , Poland Introduction and Pre-Debate Voting	
08:30-08:45	Yes: Agne Straukiene , UK	
08:45-09:00	No: Mark S. Freedman , Canada	
09:00-09:10	Discussion, Rebuttals and Post-Debate Voting	
09:10-10:00	DMT could be discontinued after prolonged stability	
09:10-09:20	Moderator: Mark S. Freedman , Canada Introduction and Pre-Debate Voting	
09:20-09:35	Yes: Per Soelberg Soerensen , Denmark	
09:35-09:50	No: Klaus Schmierer , UK	
09:50-10:00	Discussion, Rebuttals and Post-Debate Voting	
10:00-11:00	The central vein sign should be used as a diagnostic criterion	
10:00-10:10	Moderator: Konrad Rejdak , Poland Introduction and Pre-Debate Voting	
10:10-11:25	Yes: Declan Chard , UK	
10:25-10:45	No : Daniel Salo Reich , USA	
10:45-11:00	Discussion, Rebuttals and Post-Debate Voting	
11:00-11:30	Coffee Break, Exhibition & e-Posters Visit	
11:30-12:30	Plenary Session (Hall A)	
12:30-13:30	Industry Sponsored Symposium (Hall A)	
13:30-14:30	MTE	
13:30-14:30	Lunch Break, Exhibition & e-Posters Visit	

14:30-16:10	Multiple sclerosis 2	HALL C
Chair:	David Bonifacic , Croatia	
14:30-15:20	Epstein-Barr virus (EBV) is a driver of ongoing MS disease activity	
14:30-14:40	Moderator: Laszlo Vecsei , Hungary Introduction and Pre-Debate Voting	
14:40-14:55	Yes: Francesca Aloisi , Italy	
14:55-15:10	No : Gavin Giovannoni , UK	
15:10-15:20	Discussion, Rebuttals and Post-Debate Voting	
15:20-16:10	Multiple Sclerosis is progressive from onset	
15:20-15:30	Moderator: Per Soelberg Sorensen , Denmark Introduction and Pre-Debate Voting	
15:30-15:45	Yes: Floriana De Angelis , UK	
15:45-16:00	No: Giancarlo Comi , Italy	
16:00-16:10	Discussion, Rebuttals and Post-Debate Voting	
16:10-16:30	Coffee Break, Exhibition & e-Posters Visit	
16:30- 18:10	MS : Diagnosis and pathogenesis	
Chair:	Ruth Itzhaki , UK	
16:30-17:20	Microglia are the main drivers of progressive MS	
16:30-16:40	Moderator: Ron Milo , Israel Introduction and Pre-Debate Voting	
16:40-16:55	Yes: Alicja Kalinowska , Poland	
16:55-17:10	No: Gavin Giovannoni , UK	
17:10-17:20	Discussion, Rebuttals and Post-Debate Voting	
17:20-18:10	Enhancing recovery in MS	
Chairman:	Giancarlo Comi , Italy Strategies to promote remyelination: Hans Peter Hartung , Germany Advances in neurorehabilitation: Peter Feys , Belgium Role of neuromodulation in enhancing recovery: Letizia Leocani , Italy	